Abstract library

9 results for "Auernhammer".
#68 Serum chromogranin A as tumor marker in neuroendocrine tumors
Introduction: Serum chromogranin A (CgA) is used as a tumor marker for neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Svenja Nölting
#134 Gastrointestinal neuroendocrine tumors: tumor characteristics and long-term clinical outcome in the German NET registry
Introduction: Prognosis of neuroendocrine tumors (NETs) has been difficult to predict due to heterogenous tumor biology, various classification systems, and lack of reliable and recent data due to the rarity of these tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Ulrich-Frank Pape
Authors: Maasberg S, König A, Rinke A, Anlauf M, ...
#327 Long-term Results and Life Quality in Patients with Pancreatic Neuroendocrine Tumors at Munich University-Großhadern
Introduction: PNETs substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized centers, a broad interdiscipilary armentarium can be used to achieve optimal treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sabine Zahn
Authors: Zahn S, Reincke A, Hornung H, Jauch K W, ...
#739 Aspirin Inhibits Cell Viability and mTOR Signalling in Neuroendocrine Tumor Cells
Introduction: Patients with multiple endocrine neoplasia (MEN) type 1 develop pancreatic NETs as well as thymic and bronchus carcinoids. Aspirin has been reported to inhibit mTOR signalling and exhibit antitumoral activity in colorectal cancer cells. So far, no data with aspirin on NETs have been published.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Matilde P Spampatti
#742 Evaluation of Relevant Factors of Prognosis Among a Large German Multi-Centric Cohort–Results from the German NET Registry
Introduction: Neuroendocrine neoplasms (NEN) are a rare tumor entity with varying biological behavior.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Sebastian Maasberg
#743 In Vitro Anticancer Effect of Metformin on Neuroendocrine Tumor Cells
Introduction: Patients with multiple endocrine neoplasia (MEN) type 1 develop pancreatic NETs as well as bronchus carcinoids. No prophylactic drug is available yet. Metformin has been reported to act on the AMPK/mTOR signalling pathway and exhibit antitumoral activity in several cancer cell lines.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: George Vlotides
#874 The pan-TRK Inhibitor GNF5837 Inhibits Cell Viability and Akt and MAPK Signaling in Human Neuroendocrine GOT1 Tumor Cells
Introduction: The tropomyosin receptor kinase family (TRKA, TRKB, TRKC) effects tumor cell growth in various models. Recent preclinical studies in neuroendocrine carcinoma of the lung cell lines have shown that Trk receptors might be a therapeutic target for neuroendocrine neoplasias.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. Christoph Auernhammer
#1542 Selective Inhibition of PI3Kalpha (BYL719) - Promising Therapeutic Option for Neuroendocrine Tumors?
Introduction: Neuroendocrine tumors are heterogeneous, often functional malignancies and their therapeutic options are limited. As the PI3 kinase signaling is ­in GEP-NENs, selective PI3Kalpha inhibitors may be more potent than panPI3K inhibitors.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. Patricia Grabowski
#1891 GSK3: A Novel Therapeutic Target in NETs?
Introduction: GSK3 is a serine/threonine-kinase that plays a critical role in cancer. In neuroendocrine tumours (NETs) GSK3 is regularly overactivated.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Svenja Nölting